First-in-human, phase 1a dose finding of LVGN6051 CD137/4-1BB agonistic antibody with or without pembrolizumab in patients with advanced solid tumors

被引：0

作者：

Daud, Adil

Albany, Costantine

Velcheti, Vamsidhar

Hauke, Ralph J.

Ahnert, Jordi Rodon

Karp, Daniel D.

Tsimberidou, Apostolia Maria

Cohen, Julia Wanda

Schmidt, Emmett V.

Wang, Jieyi

Chan, C. Hubert

Fu, Siqing

机构：

[1] Univ Calif San Francisco, San Francisco, CA USA

[2] Horizon Oncol & Res Ctr, Lafayette, IN USA

[3] NYU, New York, NY USA

[4] Laura & Isaac Perlmutter Canc Ctr, New York, NY USA

[5] Nebraska Canc Specialists, Omaha, NE USA

[6] Univ Texas MD Anderson Canc Ctr, Houston, TX USA

[7] Merck Co Inc, Rahway, NJ USA

[8] Lyvgen Biopharma, Shanghai, Peoples R China

[9] Univ Texas MD Anderson Canc Ctr, Dept Invest Canc Therapeut, Houston, TX USA

来源：

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

2525

引用

页数：1